Home > Magazine > Asco Member News

September 2023 Member News

Sep 20, 2023

JCO’s Cancer Stories: The Art of Oncology podcast received a Gold Award during the 42nd Annual AM&P Network EXCEL Awards, as announced by the Software & Information Industry Association. EXCEL is the largest and most prestigious awards program recognizing excellence and leadership in association media, publishing, marketing, and communication. Lidia Schapira, MD, FASCO, hosts the podcast series; each episode features a reading of an Art of Oncology article, an interview with the author, and reflection on the personal experiences of those living with cancer or caring for people with cancer. Listen on Apple, Google, Spotify, and other podcast platforms. 
Ramaswamy Govindan, MD, now serves as associate chief of the Division of Oncology at Siteman Cancer Center in St. Louis. 
Research! America, a nonprofit alliance that advocates for science, discovery, and innovation to achieve better health for all, has elected four new members to its Board of Directors, including Karen E. Knudsen, PhD, MBA, and David M. Reese, MD. 
Yoshie Umemura, MD, was recently appointed chief medical officer of the Ivy Brain Tumor Center and chief of neuro-oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute. 
The James P. Allison Institute at the University of Texas MD Anderson Cancer Center has announced the appointment of its first members, including James P. Allison, PhD, Padmanee Sharma, MD, PhD, and Sangeeta Goswami, MD, PhD. This group will bring diverse expertise in immunobiology to lead groundbreaking research that will deepen the understanding of the immune system and bring the benefits of immunotherapy to all patients. 
The Society of Surgical Oncology announced that Chandrakanth Are, MBBS, MBA, FSSO, FRCS, FACS, has been named chief executive officer of the Global Forum of Cancer Surgeons. 
Nathan Denlinger, DO, MS, received a 2023 American Society of Hematology (ASH) Scholar Award for his project titled “Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin Lymphoma.” 
The ASCO Post contributed reporting. 
In Memoriam                                                                  
A. William Blackstock Jr., MD, FASCO*; Susan M. Love, MD, MBA 

Back to Top